Multiple Myeloma Treatment Strategies

Multiple myeloma is a plasma cell malignancy characterised by proliferation within the bone marrow and the production of monoclonal immunoglobulin. Treatment has evolved from conventional cytotoxic chemotherapy to a multidimensional approach encompassing autologous stem cell transplantation, targeted agents and immunotherapy. Proteasome inhibitors disrupt protein homeostasis in malignant plasma cells, while immunomodulatory drugs exert anti-tumour and microenvironmental effects. Monoclonal antibodies directed against surface antigens such as CD38 have reshaped induction and salvage regimens, often in combination with steroids and novel agents. Maintenance therapy, particularly with lenalidomide, has extended progression-free intervals and in certain subgroups improved overall survival. Emerging strategies include bispecific T-cell engagers, chimeric antigen receptor T-cell therapy and small-molecule inhibitors of nuclear export. Stratification by risk factors—cytogenetic abnormalities, minimal residual disease status and clonal heterogeneity—enables personalised treatment intensity and sequencing. Optimisation of dose, schedule and supportive care has led to substantial gains in remission rates and quality of life, yet relapse due to resistant subclones remains a challenge. Current research focuses on deepening responses, minimising toxicity and overcoming microenvironmental niches that harbour dormant cells.

Research from Nature Portfolio

Recent clinical evaluation of a quadruplet regimen adding weekly proteasome inhibition to a CD38-targeting antibody plus immunomodulatory therapy demonstrated a marked increase in minimal residual disease negativity at 18 months, establishing a new standard of care for transplant-ineligible patients. Complementing this, multi-region genomic sequencing studies have revealed spatial heterogeneity in myeloma clones, with region-specific driver mutations and evolutionary trajectories that correlate with treatment resistance. Foundational analysis of subclonal architecture has further shown that branched evolution and dynamic shifts in mutational processes influence both prognosis and therapeutic vulnerability, underscoring the need for adaptive, combination approaches that address intrapatient diversity.

Multiple Myeloma Treatment Strategies publication trend

The graph below shows the total number of articles in multiple myeloma treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Minimal residual disease (MRD): The presence of residual cancer cells at levels below conventional detection methods, assessed by sensitive sequencing or flow cytometry.

Proteasome inhibitor: A drug that blocks the proteasome complex, disrupting protein degradation and inducing apoptosis in plasma cells.

Immunomodulatory drug (IMiD): An agent that alters the tumour microenvironment, enhances immune-cell activity and has direct anti-myeloma effects.

Monoclonal antibody: A laboratory-engineered protein designed to bind a specific antigen on myeloma cells and trigger immune-mediated killing.

Clonal heterogeneity: The existence of genetically distinct subpopulations of malignant cells within a single patient, driving variable treatment responses.

References

1. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine (2024).
2. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature Communications (2017).
3. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications (2014).
4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs (2015).
5. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology (2018).
6. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia (2018).